BRYDGE SOLUTIONS

Odylia THERAPEUTICS

www.odylia.org/brydge-solutions/

Odylia Therapeutics

a nonprofit drug development company

Odylia delivers on the promise of treatments for the vastly underserved rare disease patient community. As a nonprofit drug development company, Odylia increases the chances of success for drug development, while accelerating timelines and reducing costs. We do this by focusing on the safety, efficacy, and available technologies necessary to treat each rare disease, rather than being mired in the need to generate a high return on investment.

BRYDGE SOLUTIONS

Odylia THERAPEUTICS

About Brydge Solutions

Drug development for rare diseases is often led by patients and their families. The rare disease community spends countless hours and dollars searching for and funding treatments to mitigate the effects of their rare disease. All too often, a lack of expertise can result in years of wasted money and time.

Through Brydge Solutions partnerships, Odylia reduces inefficiencies commonly found on the path from early discovery to clinical trials. With years of expertise in rare disease research, drug development, and program management, Odylia empowers Brydge Solutions program partners and provides the resources to help groups maintain momentum and control over their interests.

Teaming up to accelerate therapeutic development for rare disease

Program Leads

Ashley Winslow, PhD

CEO & CSO

Ashley has a PhD in Medical Genetics from the University of Cambridge and experience overseeing drug development from target discovery to early phase clinical programs. She brings to Odylia more than 15 years of drug development and genetic technology experience in academic, industry, and non-profit sectors.

Kathryn Post DeMott, PhD

Scientist

Kathryn has a PhD in Neuroscience from the University of British Columbia and previously worked at the Center for Rare Childhood Disorders at Translational Genomics. She has spent the last decade gaining extensive experience in the fields of neurodevelopment, neurodegeneration, neuro-ocular and drug development.



Jennifer Klein, MS

Manager of Operations & Project Management

Jennifer received her MS in Physiology from North Carolina State University. In addition to being a rare disease patient, she has experience working as a scientist developing novel compounds and repurposed drugs to treat rare and infectious disease, as well as program manager and regulatory experience in pre-clinical gene therapy products.

Additional expertise added as needed via ongoing consultant relationships in the following areas:

Preclinical gene therapy development, regulatory filing, vector manufacturing, QC/QA and data management, marketing

Accelerating therapeutic development for rare diseases through our pipeline … or yours

12 previous and ongoing partnerships since launching (2020)

Covering diverse diseases including neurodevelopmental, ocular, neurodegenerative, overgrowth disorders, multi-systemic syndromes

>70% of partnerships are with patient advocacy groups

Therapeutic modality agnostic, with extensive experience in genetic technologies

Each partnership tailored to fit the individual need of the organization



Brydge Services Shortlist

STRATEGIC BRIEF

This assessment provides a rapid assessment of therapeutic development opportunities for your disease to guide early investments and strategy development. It includes:

- Evaluation of disease understanding
- Identification of key researchers to engage
- Summary of key recommendations
- A strategic outline

LANDSCAPE ANALYSIS

This comprehensive, detailed document provides:

- In-depth review of the scientific landscape
- Strategy development including short and long-term prioritization
- Stakeholder interviews
- Recommendations for prioritization, research network expansion, timelines, and investment in critical research tools

CSO SERVICES

With this service we build a team to address your needs. Including:

- Portfolio management
- Risk assessment and mitigation
- Acceleration of drug development timelines and increased efficiencies
- Timely and consistent touch-points
- Increase organizational bandwidth and access to scientific expertise

We leverage our internal scientific and drug development expertise to provide services at a reduced rate to patient groups

Concierge Service at a glance

Innovative Partnerships at a glance

- Provided assistance navigating ineffective relationships and initiating new partnerships
- Established translational model characterization, analysis, and functionalization
- Evaluated therapeutic options, established priorities, and launched drug development efforts
- Negotiated drug repurposing, drug screening, and ASO development
- Developed plan for novel gene therapy program from initial asset design through clinical trial planning

Previous Partnership Case Studies

Odylia Partnership Established

Outcomes

sat gene b2 foundation

PURA Syndrome FOUNDATION

CLOVES SYNDROME COMMUNITY

Needs: Scientific Direction

Landscape Analyses

Scientific Guidance resulting in a focus on iPSC bank in one case and the generation of a zebrafish model in another. Feedback impacted fundraising strategy and effectiveness.

jem THERAPEUTICS

NPHP1 Family Foundation

Needs: Increased bandwidth, Assistance with lack of progress on gene therapy in development

Concierge Services

- Navigation out of previous relationship
- Generation of new gene therapy programs
- Expanded animal model use
- Evaluation of ASO option
- Initiating of drug screening (planning, execution, protocol, and partner identification
- Drug repurposing study initiated
- Managing a growing portfolio of assetts (gene therapy, ASO, small molecule)

Partner Testimonials

Mike Kaplan, MD
President & CEO, JEM Therapeutics

Our goal is to accelerate progress as quickly as possible so we sought a partner who had the depth of expertise to provide guidance on scientific strategy, but who could also give us insights into the financial and operational aspects of our company's growth. But what really stood out about Odylia was their accessibility and personal touch. They are as committed as we are to rare disease patients and that's a quality that we highly value and is critical to our success.

Kristen Davis
Executive Director, CLOVES Syndrome Community

Having a child with a rare disease means needing to become an expert in drug development. But there are so many roadblocks and things to learn. Our partnership with Odylia's Brydge Solutions helped us better understand the science of CLOVES Syndrome and gave us a fresh perspective on therapeutic options and potential collaborators for the future.

Allison Kaczenski
President, SATB2 Gene Foundation

Odylia, through Brydge Solutions, really helped the SATB2 Gene Foundation focus and start moving in the direction we need to be moving in. Their landscape analysis broke everything down into workable goals in language that could be shared with our communities.

Past and Present Partners

CLOVES SYNDROME COMMUNITY

USHER 2020 FOUNDATION

NPHP1 Family Foundation

jem THERAPEUTICS

Open Treatments

THE RDH12 FUND FOR SIGHT

Saving Jordan Avi Ogman Foundation

Research & Development of Cures for TECPR2 Genetic Disease

gene sat b2 foundation

Smith-Kingsmore SYNDROME FOUNDATION

SNOW FOUNDATION™ FOR WOLFRAM SYNDROME RESEARCH

A GLOBAL VOICE FOR RARE DISEASE

PURA Syndrome FOUNDATION

BRYDGE SOLUTIONS

Odylia THERAPEUTICS

Additional Brydge Solutions Initiatives

Odylia believes in the power of sharing information to empower the broader community around us. Through our own drug development experience and our work with partners through Brydge Solutions, we are building a publicly accessible library of resources in hopes that our learnings can help other drug development programs move faster towards the patients that need them. This means Odylia's impact goes beyond the programs we work with directly.



Where we provide free resources to help rare disease groups. We also provide links to prior Landscape Analyses and videos.



A centralized marketplace to ensure critical resources are findable and accessible for patient groups and other members of the rare disease research community.

Launching soon!

This series addresses common questions and roadblocks that face groups as they work to develop therapies.

Changing the business model, changing lives

Thank You

BRYDGE SOLUTIONS

Odylia THERAPEUTICS

Contact Us

info@odylia.org

www.odylia.org/brydge-solutions

Odylia Therapeutics

Odylia Therapeutics

Odylia Therapeutics